TIDMOXB

Oxford Biomedica PLC

31 March 2017

Hardman Research: Delivering commercial gene-therapy vector

Delivering commercial gene-therapy vector - OXB is a specialist gene and cell therapy viral-vector biopharmaceutical company. It offers vector manufacturing and development services, whilst retaining its own proprietary therapeutic candidates. Above service-fees, OXB will receive royalties on commercial products developed with its LentiVector(R) platform: extensive IP, facilities, and know-how for production and development of lentivirus vectors to generate gene-based therapies. OXB intends to out-license its five clinical candidates and to continue investment in R&D. Bioprocessing royalties are likely to result in significant upside potential in the near future.

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/oxford-biomedica-documents/31.03.17-delivering-commercial-gene-therapy-vector.pdf

 
 To contact us:      Contacts: 
  Hardman & Co        Dr Martin Hall 
  11/12 Tokenhouse    mh@hardmanandco.com 
  Yard                Dr Dorothea Hill 
  London              dmh@hardmanandco.com 
  EC2R 7AS            Dr Gregoire Pave 
                      gp@hardmanabdco.com 
                      Telephone: +44 20 7929 3399 
                      Follow us on Twitter @HardmanandCo 
 

www.hardmanandco.com

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAJMMRTMBMJBBR

(END) Dow Jones Newswires

March 31, 2017 02:15 ET (06:15 GMT)

Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Oxford Biomedica Charts.
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Oxford Biomedica Charts.